Synapse - Diane Reidy

Results (14)

Early-onset pancreatic neuroendocrine tumors: Clinical presentation, pathology features, and oncological outcomes

Journal Article

Pulvirenti, A.; Hauser, H. F.; Fiedler, L. M.; McIntyre, C. A.; Le, T.; Reidy-Lagunes, D. L.; Soares, K. C.; Balachandran, V. P.; Kingham, T. P.; D'Angelica, M. I.; more...
Annals of Surgery (2024)

Fulltext@MSK | Save

Urinary neuroendocrine neoplasms treated in the “modern era”: A multicenter retrospective review

Journal Article

Le, B. K.; McGarrah, P.; Paciorek, A.; Mohamed, A.; Apolo, A. B.; Chan, D. L.; Reidy-Lagunes, D.; Hauser, H.; Rivero, J. D.; Whitman, J.; more...
Clinical Genitourinary Cancer (2023)

Fulltext@MSK | Save

Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to lutetium-177-DOTATATE

Journal Article

Raj, N.; Coffman, K.; Le, T.; Do, R. K. G.; Rafailov, J.; Choi, Y.; Chou, J. F.; Capanu, M.; Dunphy, M.; Fox, J. J.; more...
Neuroendocrinology (2022)

Fulltext@MSK | Save

Early onset well-differentiated pancreatic neuroendocrine tumors: clinical presentation, pathologic features, and oncological outcomes

Meeting Abstract

Pulvirenti, A.; Hauser, H.; Le, T.; McIntyre, C.; Reidy-Lagunes, D.; Wei, A.; Raj, N.
Pancreas (2022)

Fulltext@MSK | Save

Treatment response and clinical outcomes of neuroendocrine neoplasms (NENs) treated with immune checkpoint inhibitors (ICIs): A single institution experience

Meeting Abstract

Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy-Lagunes, D.; Raj, N.
Pancreas (2022)

Fulltext@MSK | Save

Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well- differentiated neuroendocrine tumors (WDNETs)

Meeting Abstract

Raj, N.; Cruz, E.; Chou, J.; Capanu, M.; DeMore, A.; Hauser, H.; Heffernan, O.; Le, T.; Saltz, L.; Reidy-Lagunes, D.
Pancreas (2022)

Fulltext@MSK | Save

Treatment response and clinical outcomes of well-differentiated (WD) high-grade (HG) neuroendocrine tumors (NETs) to (177)Lu-DOTATATE

Meeting Abstract

Coffman, K.; Bodei, L.; Le, T.; Choi, Y.; Chou, J.; Capanu, M.; Dunphy, M.; Fox, J.; Grewal, R.; Reddy, R.; more...
Pancreas (2022)

Fulltext@MSK | Save

Urinary neuroendocrine neoplasms (NENs) treated in the "modern era": A multicenter retrospective review

Meeting Abstract

Le, B. K.; McGarrah, P. W.; Whitman, J.; Paciorek, A.; Raj, N.; Reidy-Lagunes, D.; Hauser, H.; Le, T.; Del Rivero, J.; Apolo, A.; more...
Pancreas (2022)

Fulltext@MSK | Save

A randomized trial evaluating patient experience and preference between octreotide long-acting release and lanreotide for treatment of well-differentiated neuroendocrine tumors